Inhaled nitric oxide as rescue therapy in severe ARDS cases due to COVID-19 pneumonia: a single center experience

Inhaled NO (iNO) has been recommended as rescue therapy in acute respiratory stress syndrome (ARDS) cases. In this study, we aimed to demonstrate the efficacy of iNO as a rescue therapy in patients with severe ARDS due to COVID-19. This retrospective study included patients with ARDS due to COVID-19...

Full description

Saved in:
Bibliographic Details
Published inEuropean review for medical and pharmacological sciences Vol. 27; no. 13; p. 6422
Main Authors Bicakcioglu, M, Kalkan, S, Duzenci, D, Yalcinsoy, M, Dogan, Z, Ozer, A B
Format Journal Article
LanguageEnglish
Published Italy 01.07.2023
Online AccessGet more information

Cover

Loading…
Abstract Inhaled NO (iNO) has been recommended as rescue therapy in acute respiratory stress syndrome (ARDS) cases. In this study, we aimed to demonstrate the efficacy of iNO as a rescue therapy in patients with severe ARDS due to COVID-19. This retrospective study included patients with ARDS due to COVID-19 who were treated with iNO between March 2020 and January 2022 in the intensive care unit (ICU) of Inonu University. Patients' files were reviewed retrospectively, and demographic data, APACHE II and Sequential Organ Failure Assessment (SOFA) scores, initiation day of iNO and duration of iNO treatment, length of stay in hospital/ICU, blood biochemistry values, complete blood counts, inflammatory parameters, arterial blood gas values, lactate, PaO2/FiO2 ratios, anti-inflammatory drugs and outcome were recorded. Data from 16 patients were reached. iNO was given at a dose of 20 ppm continuously. The mean duration of treatment with iNO was 3.5 days. All patients took the prone position except a single patient. While all patients received steroid therapy, four patients received anti-cytokine therapy, and five patients received intravenous immunoglobulin therapy. All patients were in severe ARDS with a mean PaO2/FiO2 ratio of 58 before iNO therapy. A significant increase in PaO2/FiO2 values was detected with the use of iNO (p<0.05). While three patients (19%) were discharged from the ICU, thirteen patients died. In our study, it was determined that iNO applied as a rescue treatment in patients with severe ARDS improved oxygenation. Although the effect of iNO on survival was low, it may be interpreted as clinically significant considering the severity of the general clinical condition of the patients.
AbstractList Inhaled NO (iNO) has been recommended as rescue therapy in acute respiratory stress syndrome (ARDS) cases. In this study, we aimed to demonstrate the efficacy of iNO as a rescue therapy in patients with severe ARDS due to COVID-19. This retrospective study included patients with ARDS due to COVID-19 who were treated with iNO between March 2020 and January 2022 in the intensive care unit (ICU) of Inonu University. Patients' files were reviewed retrospectively, and demographic data, APACHE II and Sequential Organ Failure Assessment (SOFA) scores, initiation day of iNO and duration of iNO treatment, length of stay in hospital/ICU, blood biochemistry values, complete blood counts, inflammatory parameters, arterial blood gas values, lactate, PaO2/FiO2 ratios, anti-inflammatory drugs and outcome were recorded. Data from 16 patients were reached. iNO was given at a dose of 20 ppm continuously. The mean duration of treatment with iNO was 3.5 days. All patients took the prone position except a single patient. While all patients received steroid therapy, four patients received anti-cytokine therapy, and five patients received intravenous immunoglobulin therapy. All patients were in severe ARDS with a mean PaO2/FiO2 ratio of 58 before iNO therapy. A significant increase in PaO2/FiO2 values was detected with the use of iNO (p<0.05). While three patients (19%) were discharged from the ICU, thirteen patients died. In our study, it was determined that iNO applied as a rescue treatment in patients with severe ARDS improved oxygenation. Although the effect of iNO on survival was low, it may be interpreted as clinically significant considering the severity of the general clinical condition of the patients.
Author Ozer, A B
Kalkan, S
Bicakcioglu, M
Dogan, Z
Yalcinsoy, M
Duzenci, D
Author_xml – sequence: 1
  givenname: M
  surname: Bicakcioglu
  fullname: Bicakcioglu, M
  email: abelinozer@gmail.com
  organization: Department of Anesthesia and Reanimation, Faculty of Medicine, Inonu University, Malatya, Turkey. abelinozer@gmail.com
– sequence: 2
  givenname: S
  surname: Kalkan
  fullname: Kalkan, S
– sequence: 3
  givenname: D
  surname: Duzenci
  fullname: Duzenci, D
– sequence: 4
  givenname: M
  surname: Yalcinsoy
  fullname: Yalcinsoy, M
– sequence: 5
  givenname: Z
  surname: Dogan
  fullname: Dogan, Z
– sequence: 6
  givenname: A B
  surname: Ozer
  fullname: Ozer, A B
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37458665$$D View this record in MEDLINE/PubMed
BookMark eNo1j9tKw0AURQdRtFZ_Qc4PBJJJJjPxrbReCoWCt9dyMtmxA-0kziTS_r2K-rRfFou1L8Wp7zxOxERKUySpltW5uMh1oUxZqon4WPot79CQd0NwlrqDa0AcKSDaETRsEbg_kvMU8YkAmj0tnslyRKTmB-hovn5bLpKsot5j3Hfe8S0xReffdyALPyAQDj2Cg7e4Emct7yKu_3YqXu_vXuaPyWr9sJzPVkmfpWZI8oLLWrWmRJ7VpmKj61wV7Xe_qpTkyrRWSoBTpIy8qisNXael5UbrTBWQU3Hz6-3Heo9m0we353Dc_H-XX00gU6M
ContentType Journal Article
DBID NPM
DatabaseName PubMed
DatabaseTitle PubMed
DatabaseTitleList PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
EISSN 2284-0729
ExternalDocumentID 37458665
Genre Journal Article
GroupedDBID NPM
ID FETCH-LOGICAL-p108t-34a6b5f86e31b89a87b354f7295952a98fc22eea0e0ae39b97e7b06cad77154e2
IngestDate Wed Oct 16 00:38:54 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 13
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p108t-34a6b5f86e31b89a87b354f7295952a98fc22eea0e0ae39b97e7b06cad77154e2
PMID 37458665
ParticipantIDs pubmed_primary_37458665
PublicationCentury 2000
PublicationDate 2023-Jul
PublicationDateYYYYMMDD 2023-07-01
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-Jul
PublicationDecade 2020
PublicationPlace Italy
PublicationPlace_xml – name: Italy
PublicationTitle European review for medical and pharmacological sciences
PublicationTitleAlternate Eur Rev Med Pharmacol Sci
PublicationYear 2023
Score 2.367617
Snippet Inhaled NO (iNO) has been recommended as rescue therapy in acute respiratory stress syndrome (ARDS) cases. In this study, we aimed to demonstrate the efficacy...
SourceID pubmed
SourceType Index Database
StartPage 6422
Title Inhaled nitric oxide as rescue therapy in severe ARDS cases due to COVID-19 pneumonia: a single center experience
URI https://www.ncbi.nlm.nih.gov/pubmed/37458665
Volume 27
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lb9QwEICtLUioFwTi_ZIP3KKgxI7z4FZ1QS2oBUGLyqkaO5MSdZtd2o0EPfPDGdvJJl2BeFyykZ2sVv7sGc_szJix5xKzLAZMw8xoYQ2UONSkWcMUDKR5CoTcJgrv7ac7h8mbI3U0mfwYRS21S_3CXP4yr-R_qFIbcbVZsv9AdvWl1ED3xJeuRJiuf8V4t_lC8r0MaFnagPj5t7pEe3AMmdCmxcDnVrnEPtJ_eI7B1ofpx8CQ4roIytYdmrH97tPuNIyLYNFgSz-8Bp_-bF0IMwxs7Caed-cAYD9B1j35Xf6LjVg86_74cfUHhrLYQ_KlwZFj3sCpqecns_aKX_YtzE7X_LLT9pJera-EKH-GmbG5a9-Hlzv3hZCrUFfSPk7MCVKQoa1fPpbJvl5AP_fkSMKSvSTGop8GZXHm-MosUbZ635971yps910bbCPLrazcf7-3yW70zWsGh9t4HNxiNzuLgW95_LfZBJs77GuHnnv03KHncME9et6h53XDPXpu0XOHnpf2gTnv0fMV-pccuAfPPXg-gL_LDl-_OtjeCbvTM8JFHOXLUCaQalXlKcpY5wXkmZYqqWigVaEEFHllhECECCNAWegiw0xHqYGSVq9KUNxj15p5gw8Yz1SBKoqBPiFJtNZxKSNRlcLQ7lPn8iG770foeOFLpBz3Y_fotz2P2eYwHZ6w6xWtSXxKG7ylfuYI_AQYBlgV
link.rule.ids 783
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhaled+nitric+oxide+as+rescue+therapy+in+severe+ARDS+cases+due+to+COVID-19+pneumonia%3A+a+single+center+experience&rft.jtitle=European+review+for+medical+and+pharmacological+sciences&rft.au=Bicakcioglu%2C+M&rft.au=Kalkan%2C+S&rft.au=Duzenci%2C+D&rft.au=Yalcinsoy%2C+M&rft.date=2023-07-01&rft.eissn=2284-0729&rft.volume=27&rft.issue=13&rft.spage=6422&rft_id=info%3Apmid%2F37458665&rft_id=info%3Apmid%2F37458665&rft.externalDocID=37458665